DiagnoCure
DiagnoCure Board Votes to Liquidate, Dissolve Company
The plan, which is subject to shareholder approval, comes after the company failed to find buyers for its prostate and colorectal cancer tests.
DiagnoCure's Q4 Revenues Fall as Net Loss Widens
The life sciences company said the loss is mostly attributable to a decrease in royalty revenue from its PCA3 prostate cancer biomarker assets.
DiagnoCure Sells PCA3 Prostate Cancer Assets to Hologic's Gen-Probe for C$6.5 Million
Hologic will purchase the assets via its subsidiary Gen-Probe, from which DiagnoCure will repurchase Series A shares worth C$1 million.
DiagnoCure Q1 Revenues Dip 3 Percent
The firm also said that it is looking for marketing partners for its multimarker urine-based prostate cancer test, which was validated in 500 patients.
In Brief This Week: Agilent Technologies; Diagnocure; KineMed, Pfizer; PositiveID; SomaLogic
NEW YORK (GenomeWeb) – Agilent Technologies said this week that it has mad an adjustment to its second quarter 2014 GAAP net income.
Jun 5, 2014
Jun 3, 2013
DiagnoCure's Q2 Revenues Fall 85 Percent
Mar 11, 2013
DiagnoCure Q1 Revenues Slide 70 Percent
Mar 30, 2012
DiagnoCure's Q1 Revenues Jump 90 Percent
Sep 9, 2011
DiagnoCure's Q3 Revenues Shrink 12 Percent
Aug 17, 2011
Canada Approves Gen-Probe's Prostate Cancer Assay
Jul 5, 2011
Aug 25, 2010
DiagnoCure Retains JMP to Help with Lab Business
Aug 3, 2010
DiagnoCure Laboratory Gets New York Permit
Oct 5, 2009
DiagnoCure, Lab21 Ink UK Sales Pact
Jun 9, 2009